Outcomes of polymyalgia rheumatica in real-world practice: a longitudinal cohort study

1 WEYAND CM, GORONZY JJ. Giant-Cell Arteritis and Polymyalgia Rheumatica. New England Journal of Medicine. 2014;371(1):50-7. Search in Google Scholar

2 CHARLTON R. Optimal management of giant cell arteritis and polymyalgia rheumatica. Therapeutics and Clinical Risk Management. 2012:173-9. Search in Google Scholar

3 GIOVANNA COLOMBO M, WETZEL A-J, HAUMANN H, DALLY S, KIRTSCHIG G, JOOS S. Polymyalgia Rheumatica: Sex-Specific Epidemiology, Diagnostic and Therapeutic Approach, and Medical Care. Deutsches Ärzteblatt International. 2022;119(24). Search in Google Scholar

4 CHAMI SEI, JASON M SPRINGER JM. Update on the treatment of giant cell arteritis and polymyalgia rheumatica. The Medical clinics of North America. 2021;105(2):311-324. Search in Google Scholar

5 DASGUPTA B, CIMMINO MA, KREMERS HM, SCHMIDT WA, SCHIRMER M, SALVARANI C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis & Rheumatism. 2012;64(4):943-54. Search in Google Scholar

6 OSTERBERG L, BLASCHKE T. Adherence to medication. New England Journal of Medicine. 2005;353(5):487-97. Search in Google Scholar

7 LEE JH, CHOI ST, KIM JS, YOON BY, KWOK S-K, KIM H-S, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatology international. 2013;33:1475-80. Search in Google Scholar

8 MATTESON EL, MARADIT-KREMERS H, CIMMINO MA, SCHMIDT WA, SCHIRMER M, SALVARANI C, et al. Patient-reported outcomes in polymyalgia rheumatica. The Journal of rheumatology. 2012;39(4):795-803. Search in Google Scholar

9 EXLEY AR, BACON PA, LUQMANI RA, KITAS GD, GORDON C, SAVAGE CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis and Rheumatism. 1997;40:371–80. Search in Google Scholar

10 KERMANI TA, SREIH AG, CUTHBERTSON D, CARETTE S, HOFFMAN GS, KHALIDI NA, et al. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018;57(2): 322–328. Search in Google Scholar

11 EMAMIFAR A, HESS S, ELLINGSEN T, DUE KAY S, CHRISTIAN BANG J, GERKE O, et al. Prevalence of newly diagnosed malignancies in patients with polymyalgia rheumatica and giant cell arteritis, comparison of 18F-FDG PET/CT scan with chest X-ray and abdominal ultrasound: data from a 40 week prospective, exploratory, single centre study. Journal of Clinical Medicine. 2020;9(12):3940. Search in Google Scholar

12 BIRRA D, BOSELLO SL, PELUSO G, ZOLI A. Sixth-month remission as a predictor for twelve-month remission in polymyalgia rheumatica. Clin Exp Rheumatol. 2020;38(3):436-41. Search in Google Scholar

13 PERRICONE C, CAFARO G, FIUMICELLI E, BURSI R, BOGDANOS D, RICCUCCI I, et al. Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica. Clin Exp Med. 2022. Search in Google Scholar

14 HATTORI K, HIRANO Y, KOJIMA T. Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone. Int J Rheum Dis. 2020;23(11):1581-6. Search in Google Scholar

15 AOKI A, KOBAYASHI H, YAMAGUCHI Y. Predictors of long-term therapy with glucocorticoid in polymyalgia rheumatica. Modern Rheumatology. 2021;31(2):417-20. Search in Google Scholar

16 NARVÁEZ J, NOLLA-SOLÉ JM, CLAVAGUERA MT, VALVERDE-GARCÍA J, ROIGESCOFET D. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol. 1999;26(9):1945-52. Search in Google Scholar

17 ALBRECHT K, HUSCHER D, BUTTGEREIT F, ARINGER M, HOESE G, OCHS W, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatology international. 2018;38(4):569-77. Search in Google Scholar

18 CANTINI F, SALVARANI C, OLIVIERI I, MACCHIONI L, RANZI A, NICCOLI L, et al., editors. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Seminars in arthritis and rheumatism; 2000;30(1):17-24. Search in Google Scholar

19 KHABBAZI A, ALINEJATI B, HAJIALILO M, GHOJAZADEH M, MAHDAVI AM. Cigarette smoking and risk of primary systemic vasculitis: a propensity score matching analysis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. 2019;36(3):243. Search in Google Scholar

20 MACKIE SL, HENSOR EM, HAUGEBERG G, BHAKTA B, PEASE CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology. 2010;49(4):716-22. Search in Google Scholar

21 SALVARANI C, CANTINI F, MACCHIONI P, OLIVIERI I, NICCOLI L, PADULA A, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective follow up study. Arthritis & Rheumatism. 1998;41(7):1221-6. Search in Google Scholar

22 CECCATO F, ROVERANO SG, PAPASIDERO S, BARRIONUEVO A, RILLO OL, PAIRA SO. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. JCR: Journal of Clinical Rheumatology. 2006;12(4):167-71. Search in Google Scholar